Sanofi Defends Lyxumia Under Scrutiny at Diabetes Meeting

Sanofi defended its experimental drug Lyxumia after some scientists questioned the medicine’s novelty at a diabetes conference.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.